Selectis Health (GBCS) director David Furstenberg exits board and Audit Committee
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Selectis Health, Inc. reported that David Furstenberg resigned as a member of its Board of Directors and Audit Committee, effective immediately on March 30, 2026. The company expressed appreciation for his generous service and support, and the report was signed by CEO Adam Desmond.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Terms
Board of Directors, Audit Committee, Emerging growth company
3 terms
Board of Directors financial
"resignation as a member of the Board of Directors and Audit Committee"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
Audit Committee financial
"resignation as a member of the Board of Directors and Audit Committee"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
Emerging growth company regulatory
"Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did Selectis Health, Inc. (GBCS) disclose in this 8-K filing?
Selectis Health, Inc. disclosed that director David Furstenberg resigned from its Board of Directors and Audit Committee, effective March 30, 2026. The company thanked him for his generous service and support, and the report was signed by CEO Adam Desmond.
When did Selectis Health (GBCS) director David Furstenberg resign?
Director David Furstenberg resigned from Selectis Health, Inc. effective March 30, 2026. His resignation covered both his role on the Board of Directors and on the Audit Committee, as disclosed in the company’s current report signed by CEO Adam Desmond.
Which positions did David Furstenberg leave at Selectis Health (GBCS)?
David Furstenberg resigned as a member of the Board of Directors and the company’s Audit Committee. His resignation was effective immediately on March 30, 2026, and Selectis Health publicly thanked him for his generous service and support in these governance roles.
Who signed the Selectis Health (GBCS) report announcing the resignation?
The report announcing David Furstenberg’s resignation was signed by Adam Desmond, Chief Executive Officer of Selectis Health, Inc. His signature on behalf of the registrant formally certifies the disclosure under the Securities Exchange Act of 1934 requirements.
What committee change was disclosed by Selectis Health (GBCS)?
Selectis Health, Inc. disclosed that David Furstenberg resigned from its Audit Committee, in addition to leaving the Board of Directors. This change was effective March 30, 2026, and was communicated as part of a current report signed by CEO Adam Desmond.